The ANCHOR trial, sponsored by Baylor College of Medicine, targets relapsed or refractory B-cell malignancies, a significant unmet medical need with limited treatment options. The combination of CAR technology with NKT cells and IL-15 aims to enhance therapeutic efficacy and patient outcomes. Given the increasing interest in CAR therapies, particularly in hematological cancers, successful results could position this therapy competitively against existing CAR-T therapies, such as those targeting CD19. The trial's focus on a unique cell type (NKT cells) may provide a novel approach that could differentiate it in the market. The potential for long-term follow-up (up to 15 years) may also appeal to investors and stakeholders concerned with safety and efficacy over time.